Sandoz announces first patient enrolled in clinical study for proposed biosimilar denosumab in osteoporosis

  • Integrated Phase I/lll study for proposed biosimilar denosumab to confirm matching efficacy, safety and immunogenicity with reference medicine[1] 
  • Osteoporosis accounts for 8.9m bone fractures annually, including debilitating hip fractures — number set to increase substantially over next two decades[2]
  • Sandoz has eight marketed biosimilar medicines globally and 10+ molecules in the pipeline including proposed biosimilar denosumab

Holzkirchen, July 22, 2019 – Sandoz, a Novartis division and a global leader in …

/by

Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased

  • Continuing operations[1] net sales up 8% (cc[2], +4% USD) driven by:
    • Cosentyx at USD 858 million, +25% (cc) mainly driven by continued strong US growth (+31%)
    • Entresto grew to USD 421 million, +81% (cc) with increased initiation in hospital and ambulatory settings
    • Oncology sales grew 9% (cc) driven by growth from Lutathera (USD 109 million), Kisqali (USD 111 million) and Kymriah (USD 58 million) in the second quarter
    • Sandoz sales grew 3% (cc, -1% USD) as ex-US growth more than …
/by

Sandoz extends SYMJEPI™ (epinephrine) Injection launch to US pharmacies to help improve patient access to life-saving medicine

  • Adult and pediatric doses immediately available as single-dose, pre-filled syringe and device combination for emergency treatment of Type 1 allergic reactions, including anaphylaxis1
  • SYMJEPI will help address critical impact of ongoing epinephrine auto-injector shortages2 for the one in 50 Americans at risk for anaphylaxis3
  • Sandoz is committed to helping people access high quality healthcare at affordable prices, with strong focus on areas of unmet patient need

Princeton, New …

/by

Sandoz launches oncology generic gefitinib in 13 EU countries at loss of market exclusivity, expanding access to essential medicine

  • Sandoz gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer[1] with activating mutations of EGFR-TK[1]
  • More than 300,000 European men and women are diagnosed with lung cancer annually, making it the fourth most common cancer[2]
  • With launch Sandoz builds on robust 50+ medicine oncology portfolio globally, including chemotherapy, targeted therapy, hormones and supportive care[3]

Holzkirchen, Germany, July 2, 2019 – Sandoz today announced the launch of the generic …

/by